FDA Approves CABERGOLINE — SOLA Pharmaceuticals, LLC

# FDA Approves SOLA Pharmaceuticals' Generic Cabergoline The FDA has approved SOLA Pharmaceuticals' abbreviated new drug application for generic cabergoline oral tablets, potentially increasing market competition in the prolactin-lowering medication segment and providing patients with a more affordable treatment option for conditions such as hyperprolactinemia and prolactinomas.